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ABSTRACT 
Background New therapeutic options are needed for patients with heavily pretreated breast 
cancer. Etirinotecan pegol is a long-acting topoisomerase-I inhibitor designed to provide 
prolonged tumour-cell exposure to SN38, the active metabolite. We aimed to assess the efficacy 
and safety of two etirinotecan pegol dosing schedules in patients with previously treated 
metastatic breast cancer to determine an optimum dosing schedule for phase 3 trials. 
Methods In this randomised, two-stage, open-label phase 2 trial, we recruited patients aged 18 
years or older who had received taxane therapy and undergone two or fewer previous 
chemotherapy regimens for metastatic breast cancer, with an Eastern Cooperative Oncology 
Group performance status of 0 or 1, from 18 sites in three countries. Eligible patients were 
randomly assigned (1:1) to etirinotecan pegol 145 mg/m2 every 14 days or every 21 days. The 
primary endpoint was the proportion of patients with a confirmed objective response as defined 
by Response Evaluation Criteria in Solid Tumors version 1.0, analysed by intention to treat. 
Safety was assessed in all patients who received at least one dose of study drug. This trial is 
registered at ClinicalTrials.gov, number NCT00802945. 
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Findings 70 patients (35 in each group) were randomly assigned to treatment between Feb 17, 
2009 and April 13, 2010. Of the 70 patients, 20 (29%; 95% CI 18.4-40.6) achieved an objective 
response (two [3%] had a complete response and 18 [26%] had a partial response). Ten 
patients on the 14-day schedule achieved an objective response (29%; 95% CI 14.6-46.3; eight 
partial responses, two complete responses) as did ten on the 21-day schedule (29%; 95% CI 
14.6-46.3; all partial responses). The most common grade 3 or worse adverse events were 
delayed diarrhoea (seven [20%] of 35 patients on the 14-day schedule vs eight [23%] of 35 
patients on the 21-day schedule), fatigue (five [14%] vs three [9%]), neutropenia (four [11%] vs 
four [11%]), and dehydration (three [9%] vs four [11%]); 14 [20%] patients discontinued 
treatment because of drug-related toxicity. There were two possible drug-related deaths (acute 
renal failure and septic shock) in the 14-day group; other drug-related serious adverse events 
reported by more than one patient included ten [14%] patients with diarrhoea (six [17%] 
patients on the 14-day schedule vs four [11%] on the 21-day schedule), six [9%] with 
dehydration (two [6%] vs four [11%]), two [3%] with nausea (two [6%] vs none), and two [3%] 
with vomiting (two [6%] vs none). 
Interpretation On the basis of the overall clinical data, pharmacokinetics, and tolerability profile, 
etirinotecan pegol 145 mg/ m2 every 21 days has been selected for a phase 3 trial against 
treatment of physician’s choice in patients with advanced breast cancer. 
Funding Nektar Therapeutics 
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With less than 25% of patients diagnosed with metastatic breast cancer surviving for 5 years, 
new treatments are urgently needed—especially for those patients who have disease 
progression after receiving anthracyclines, taxanes, and capecitabine.1 The activity of newer 
drugs is unsatisfactory in these heavily pretreated patients—eg, only 9-12% of patients who 
receive eribulin and ixabepilone in this setting achieve an objective response, with median 
progression-free survival (PFS) between 2.6 months to 3.1 months.2,3 
Etirinotecan pegol (NKTR-102) is a long-acting topoisomerase-I inhibitor derived from 
camptothecin. It consists of the topoisomerase-I inhibitor irinotecan bound to a proprietary 
polyethylene glycol core by a biodegradable linker. The linker slowly hydrolyses in vivo to form 
SN38, the active moiety of etirinotecan pegol. The drug is designed to provide continuous 
exposure to SN38 while reducing the toxicities associated with excessively high irinotecan and 
SN38 plasma concentrations reported in patients who receive irinotecan directly. In the initial 
phase 1 clinical trial,4,5 etirinotecan pegol resulted in sustained and controlled exposure to SN38, 
which had a mean half-life of about 50 days. Preclinical and clinical studies of etirinotecan pegol 
have provided encouraging evidence of enhanced antitumour activity and less haematopoietic 
toxicity than with irinotecan.6-12 In the phase 1 study,4,5 three schedules of etirinotecan pegol 
were investigated, two of which (one dose every 2 or 3 weeks) established a recommended dose 
for future study of 145 mg/m2. Although no dose-limiting toxicity was reported at this dose on 
either schedule, a dose of 145 mg/ m2 was regarded as optimum for future investigation because 
of the long terminal elimination half-life of SN38 and the observation that four of 12 patients had 
grade 3 diarrhoea after the first cycle (the dose-limiting toxicity observation period). 
Etirinotecan pegol showed promising activity with confirmed partial responses reported in eight 
patients with various cancers, including a patient with triple-negative breast cancer, 
accompanied by limited myelotoxicity.4,5 
Previously reported activity of irinotecan in patients with metastatic breast cancer supported 
the idea that exposure to a drug with a different mechanism of action from that of tubulin-
targeted agents or antimetabolites might result in enhanced clinical benefit. In a phase 2 trial, an 
irinotecan dose of 100 mg/ m2 per week had more favourable activity (objective response 23%; 
median PFS 2.8 months) than did a dose of 240 mg/m2 every 3 weeks (objective response 14%; 
median PFS 1.9 months), suggesting that more continuous exposure to SN38 might be 
beneficial.13 
In this phase 2 study, we aimed to assess the efficacy and safety of two different schedules of 
etirinotecan pegol in patients with metastatic breast cancer to provide further evidence for the 
best possible dosing schedule for future phase 3 investigations. 
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STUDY DESIGN AND PATIENTS 
This study was a randomised, two-stage, open-label phase 2 trial that recruited patients from 18 
sites in three countries (five sites in Belgium, seven sites in the USA, and six sites in the UK; 
appendix). 
Eligible patients were those aged 18 years or older with inoperable metastatic breast cancer 
who had undergone two or fewer previous chemotherapy regimens in a metastatic setting, had 
received taxane therapy (adjuvant or metastatic setting), and had measurable disease, an 
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and adequate organ 
and bone marrow function. Exclusion criteria consisted of chemotherapy, radiotherapy or major 
surgery within 4 weeks of enrolment, no recovery from grade 2 or worse toxicity from previous 
chemotherapy, concomitant use of biological agents (including bevacizumab or trastuzumab) or 
investigational agents, previous treatment with a camptothecin derivative, administration of 
cytochrome P450 inducers or inhibitors, pregnancy or lactation, a history of intolerance to 
pegylated drugs, CNS metastases, or inflammatory or unresolved bowel disease. 
The protocol and patient materials (informed consent documentation and patient information 
forms) were approved by the independent ethics committee for each site. The study was done in 
accordance with the International Conference on Harmonisation guidelines concerning Good 
Clinical Practice and the Declaration of Helsinki. All participants provided informed consent. 
Figure 1: Trial profile 
 
*One patient was transferred to a continuation protocol. 
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RANDOMISATION AND MASKING 
Patients were randomly assigned (1:1) to two treatment groups: 145 mg/ m2 etirinotecan pegol 
given every 14 or 21 days. Randomisation was done with an interactive voice or web response 
system by a contract research organisation (PPD, Wilmington, NC, USA). PPD also provided 
medical, clinical, pharmacovigilance, and database support, did regulatory filings, and offered 
interactive voice response system and drug supply support from study start throughout the trial. 
PPD (until Jan 1, 2010) and Nektar Therapeutics (Jan 1, 2010, onwards) reviewed patient 
eligibility data and provided approval for patients to proceed to randomisation. Stratification 
was not done. The system restricted the number of randomly assigned patients per site to ten. A 
permuted block size of two was used; the investigators and the sponsor were masked to the 
block size. Because of the nature of the two different dosing regimens, masking of the patients, 
investigators, and those analysing the data was not feasible. 
PROCEDURES 
Patients received etirinotecan pegol hydrochloride triflutate in lactate buffer (drug substance 
was made by Carbogen AMCIS, Bubendorf, Switzerland; drug product was manufactured by 
Baxter Oncology, Halle/Westfalen, Germany) at 145 mg/ m2 every 14 days or 145 mg/ m2 every 
21 days as an intravenous infusion for 90 min. Patients continued to receive treatment every 14 
or 21 days until disease progression, or unacceptable toxicity. Etirinotecan pegol was dose-
reduced by 25 mg/m2 for grade 3-4 haematological toxicity, grade 3-4 diarrhoea, or other grade 
2-4 non-haematological toxicities (other than alopecia, anorexia, asthenia, untreated nausea, or 
vomiting). The re-treatment protocol required that a new cycle of therapy should not begin until 
the following were reached: neutrophils count of 1500 per μL or more; platelets count of 
100000 per μL or more; haemoglobin count of 90 g/L or more, resolution of all treatment-
related diarrhoea to grade 0, and recovery of any other treatment-related non- haematological 
grade 1 toxicity. The protocol recommended that diarrhoea be managed with loperamide, with a 
dose of 4 mg at the first instance of loose stool or diarrhoea, and thereafter 2 mg every 2 h (4 mg 
every 4 h at night) until diarrhoea cessation.  
Myeloid growth factors were administered at the discretion of the investigator. Prophylactic 
premedications (including antihistamines, steroids, and atropine) were not needed. 
Patients had a physical examination, serum CA27-29 test, complete blood count with a blood 
differential test, and serum chemistry analysis at screening, on the first dose of each cycle, and at 
end of treatment. Radiological examination occurred at screening (within 28 days of first day of 
treatment) and every 6 weeks thereafter until progressive disease, start of new anticancer 
therapy, or end of study. Patients were contacted every 3 months after the end of treatment to 
assess progression (in the absence of progression on study), survival, receipt of subsequent 
anticancer therapy, and resolution of toxicity. 
Safety laboratory assessments were analysed at a central laboratory (Quest Diagnostics Clinical 
Trials, Valencia, CA, USA); local laboratories could be used for clinical management. We 
measured response by Response Evaluation Criteria In Solid Tumors (RECIST) version 1.014 and 
graded toxicities according to the National Cancer Institute Common Terminology Criteria for 
Adverse Events version 3.0. 
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The primary endpoint was the proportion of patients who achieved an objective response (their 
best response to treatment at any time during the study), with confirmation of all responses by a 
second imaging procedure at least 28 days from the initial observation of response. Secondary 
endpoints were PFS (defined as time from randomisation to progression or death), overall 
survival, 6-month survival, 1-year survival, and safety. Exploratory analyses included 
assessment of change from baseline in CA27-29 concentration, and UGT1A1 and ABCC2 
polymorphism status, and their associations with selected toxicities. 
Table 1: Baseline characteristics 
 Etirinotecan pegol 
145 mg/m2 every 
14 days (n=35) 
Etirinotecan pegol 
145 mg/m2 every 
21 days (n=35) 
Age, years 53.0 (33-83) 56.0 (37-77) 
Women 34(97%) 35 (100%) 
Ethnic origin 
White 31 (89%) 33 (94%) 
Black 2 (6%) 2 (6%) 
Asian 1 (3%) 0 
Other 1 (3%) 0 
ECOG performance status 
0 15 (43%) 13 (37.1%) 
1 20 (57%) 22 (63%) 
Postmenopausal 24 (71%)* 29 (83%) 
Time from initial diagnosis to first dose of study drug, years 4.0 (0-15) 5.4 (1-19) 
Time from initial diagnosis to metastatic disease, years 1.5 (0-7) 2.0 (0-12) 
Receptor status 
Oestrogen-receptor positive 21 (60%) 20 (57%) 
Progesterone-receptor positive 11 (31%) 13 (37%) 
HER2 positive 3 (9%) 2 (6%) 
Triple negative† 11 (31%) 10 (29%) 
Visceral disease 28 (80%) 32(91%) 
Number of previous cytotoxic regimens in metastatic setting 1.0 (0-3) 2.0 (0-2) 
Any previous cytotoxic regimen in metastatic setting 34(97%) 34(97%) 
1 previous cytotoxic regimen 17 (49%) 9 (26%) 
2-3 previous cytotoxic regimens 17 (49%) 25 (71%) 
Previous systemic treatments‡ 
Taxane 35 (100%) 35 (100%) 
Anthracycline 31 (89%) 31 (89%) 
Capecitabine 9 (26%) 10 (29%) 
Anthracyline/taxane 23 (66%) 21 (60%) 
Anthracycline/taxane/capecitabine 8 (23%) 10 (29%) 
Previous cytotoxic neoadjuvant or adjuvant therapy 27 (77%) 24 (69%) 
Previous adjuvant anthracycline 15 (43%) 17 (49%) 
Previous adjuvant taxane 9 (26%) 5 (14%) 
Previous adjuvant anthracycline and/or taxane 19 (54%) 18 (51%) 
Data are median (range) and number (%). ECOG=Eastern Cooperative Oncology Group. *Out of women only (n=34). 
†Oestrogen-receptor negative, progesterone-receptor negative, and HER2 negative. ‡In adjuvant or metastatic setting. 
STATISTICAL ANALYSIS 
The trial was not prospectively designed to compare the individual groups with each other, 
because a sample size of 35 patients per group would be insufficiently powered to show any 
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significant result, nor was the trial intended to be compared with a historical control in breast 
cancer. We planned to assess the efficacy and safety in each group independently with Simon’s 
two-stage design. For each group, patient enrolment occurred in two successive stages: during 
stage 1, 20 patients were to be enrolled and treated. If one or more responses were noted in 20 
assessable patients per group, 15 additional patients would be enrolled in stage 2. If five or more 
of the 35 patients responded, the drug would meet the efficacy threshold. The sample sizes for 
each stage were chosen on the basis of the null hypothesis (ie, that 5% or fewer of patients 
assigned to the study drug would have an objective response according to RECIST criteria) and 
the alternative hypothesis (ie, that 20% or more of patients assigned to the study drug would 
have an objective response according to RECIST criteria). In previous studies, an objective 
response of 20% or greater was selected as showing promising antitumour activity that justified 
further clinical development, and an objective response of 5% or less was regarded as evidence 
of insufficient antitumour activity to justify further development; a null hypothesis using a 5% 
objective response has been used in similar phase 2 trials.2,3,15,16 The type 1 error was 0.029 
(target 0.050) and the type 2 error was 0445 (target 0.20). 
We defined three populations for analysis: intention-to- treat, efficacy assessable, and safety. 
The intention-to- treat population was the primary population for all efficacy analyses and 
included all randomly assigned patients. The efficacy assessable population included all 
randomly assigned patients with measurable disease that had at least one tumour assessment 
after study drug administration or had disease progression or died within 6 weeks of the first 
study drug administration. The safety population consisted of all patients who received at least 
one dose of study drug. 
Summary statistics were used for continuous variables, and frequency counts and percentages 
were used for categorical variables. 95% CIs were calculated for objective response using the 
exact method. Time-to-event variables were estimated using the Kaplan-Meier method. All 
analyses were done with SAS software version 9.1.3. 
This study is registered at ClinicalTrials.gov, number NCT00802945. 
ROLE OF THE FUNDING SOURCE 
The sponsor of the study was involved in study design, data collection, data analysis, and 
interpretation of the results. During the study, the primary data were obtained and managed by 
the sponsor (including ALH and CZ); at study conclusion, data were analysed by statisticians 
employed by the sponsor (including CZ), and the detailed clinical study report was first drafted 
by the sponsor (including ALH) and made available to the corresponding author (AA). The 
Article was written by the corresponding author (AA), and was amended after review by all 
authors. The sponsor and corresponding author had full access to all raw data in the study; all 
authors had final responsibility for the decision to submit for publication. 
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Between Feb 17, 2009, and April 13, 2010, 70 patients were randomly assigned; 35 patients to 
each group (figure 1). At time of database lock, 69 patients were off study-drug treatment; one 
patient (with stable disease after 18 months of therapy) was transferred to a continuation 
protocol. The median age was 544 years (range 33-83), 28 (40%) patients had an ECOG 
performance status of 0, and 42 (60%) had an ECOG performance status of 1. The median 
number of cytotoxic regimens for metastatic breast cancer was two (range none to three; table 
1); one patient, on the 14-day schedule, had been inappropriately enrolled because she had 
received three previous regimens for metastatic disease. All 70 patients had received a taxane 
(53 [76%] patients had received docetaxel; 28 [40%] patients had received paclitaxel); 62 
(89%) patients had received a previous anthracycline (44 [63%] epirubicin; 17 [24%] 
doxorubicin; one [1%] mitoxantrone); 19 (27%) patients had received capecitabine. 15 (21%) 
patients had received previous bevacizumab (seven [20%] on the 14-day schedule and eight 
[23%] on the 21-day schedule). Baseline characteristics were generally balanced between 
groups with a small number of exceptions (table 1). Of the five patients with HER2-positive 
disease, all had received previous trastuzumab; none had received previous lapatinib. 
Table 2. Objective response in the intention-to-treat population 
 Etirinotecan pegol 
145 mg/m2 every 14 
days (n=35) 
Etirinotecan pegol 
145 mg/m2 every 21 
days (n=35) 
Objective tumour response* 10 (29%) 10 (29%) 
95% exact CI 14.6-46.3 14.6-46.3 
Complete response 2 (6%) 0 
Partial response 8 (23%) 10 (29%) 
Stable disease 16 (46%) 15 (43%) 
>6 months 3 (9%) 7 (20%) 
<6 months 13 (37%) 8 (23%) 
Progressive disease 9 (26%) 10 (29%) 
Clinical benefit† 13 (37%) 17 (49%) 
95% exact CI 21.5-55.1 31.4-66.0 
Median duration of response, months 8.3 4.2 
95% CI of median 2.3-14.0 2.3-5.9 
Data are number (%) or 95% CI. *Complete response or partial response. †Complete reponse, partial response, or 
stable disease for ≥6 months. 
For both schedules, more than the minimum number of objective responses needed to move into 
the second stage of the study were recorded (four of the first 20 patients for the 14-day 
schedule; five of the first 20 patients for the 21-day schedule). A confirmed objective response 
was recorded in 20 (29%, 95% CI 18.4-40.6) of 70 patients in the intention-to-treat population 
(two with a complete response and 18 with a partial response); ten patients achieved an 
objective response in each dosing schedule (table 2). 13 (37%, 95% CI 214-55 4) patients on the 
14-day schedule and 17 (49%, 31.4-66.0) patients on the 21-day schedule had some form of 
clinical benefit (either a confirmed partial or whole RECIST response, or maintenance of stable 
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disease for ≥6 months; table 2). Of the 18 patients with a partial response, four (two [6%] in 
each group) had complete resolution of target lesions with unresolved non-target lesions (such 
as bone lesions). 
Figure 2. Secondary outcomes 
 
Progression-free survival (A) and overall survival (B) in the intention-to-treat population. Circles show censored 
patients. In the tables, data are number (%), median (IQR), and 95% CI. An event in (A) is either progression or death; 
and event in (B) is death. 
The efficacy assessable population consisted of 64 patients: four patients on the 14-day schedule 
who did not have post-baseline tumour assessments were excluded because of patient 
withdrawal (n=2), an adverse event (n=1), and an investigator decision to remove the patient 
because of symptom deterioration (n=1); two patients on the 21-day schedule were excluded 
because of an adverse event (n=1) and an investigator decision because of symptom 
deterioration (n=1). For the efficacy assessable population, 20 (31%, 95% CI 20.2-44.1) 
patients achieved an objective response (ten in each group). 
In the intention-to-treat population, median PFS was 4.7 months (95% CI 23-5 3). Overall, 
median PFS was 3 3 months (2.6-5.7) for patients on the 14-day schedule, and 5.6 months (1.8-
6.2) for patients on the 21-day schedule (figure 2A). Median overall survival for the whole 
population was 10.3 months (95% CI 8.8-15.0); it was 8.8 months (5.4-15.0) for patients in the 
14-day group and 13.1 months (9.2-19.2) for patients in the 21-day group (figure 2B). 6-month 
overall survival was 57.1% (95% CI 39.3-71.5) for patients on the 14-day schedule compared 
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with 82.9% (65 3.8-91.9) patients on the 21-day schedule. 12-month overall survival was 
423.9% (95% CI 26.4-58.3) and 51.4% (34.0-66.4), respectively. 
In exploratory analyses, efficacy variables were further examined in subsets of patients who 
have the poorest outcomes—specifically, patients with triple-negative breast cancer and 
patients who had received previous anthracycline and taxane or anthracycline, taxane, and 
capecitabine. Measures of efficacy were generally more favourable for all patients on the 21-day 
schedule, particularly in patients who had previously received anthracycline, taxane, and 
capecitabine (table 3). Objective response outcomes were also calculated for patients who had 
received zero, one, or two to three cytotoxic regimens for metastatic disease (appendix). 
The safety population consisted of all 70 patients. Patients in each group received a median of 
six cycles (range 1-40 in 14-day group; 1-21 in 21-day group), with a longer median duration of 
treatment for patients on the 21-day schedule than for those on the 14-day schedule (130 days 
[range 21-440] vs 98 days [14-560]); 15 patients (seven [20%] on the 14-day schedule and eight 
[23%] on the 21-day schedule) had more than 6 months of therapy. Patients on the 14-day 
schedule had a greater median dose intensity than did those on the 21-day schedule (70.9 
mg/m2 per week [range 42-76] vs 45.6 mg/m2 per week [33-55]). In view of the long elimination 
half-life of SN38, dose delays were needed for ten (14%) patients overall with any-grade 
diarrhoea (six [17%] on the 14-day schedule vs four [11%] on the 21-day schedule; appendix). 
Dose delays and reductions were also required for ten (14%) patients with grade 2 or worse 
neutropenia (four [11%] vs six [17%]). Dose delay or reduction for grade 3 or worse toxicity 
occurred in 21 (30%) of the 70 patients (12 [34%] patients on the 14-day schedule vs nine 
[26%] patients on the 21-day schedule), including grade 3 diarrhoea, fatigue, and neutropenia. 
An additional 14 (20%) patients underwent dose delay or reduction for grade 1-2 toxicities 
(four [11%] vs ten [29%]; mainly dose delay for diarrhoea). 
Both grade 3 and worse and serious adverse events occurred more frequently in patients on the 
14-day schedule than in those on the 21-day schedule (table 4). The most common grade 3 or 
worse treatment-emergent adverse events across schedules were diarrhoea, fatigue, 
dehydration, neutropenia, and vomiting (table 4). There were two possible drug-related deaths 
(acute renal failure and septic shock) in the 14-day group; other drug- related serious adverse 
events reported by more than one patient included ten [14%] patients with diarrhoea (six 
[17%] patients on the 14-day schedule vs four [11%] on the 21-day schedule), six [9%] with 
dehydration (two [6%] vs four [11%]), two [3%] with nausea (two [6%] vs none), and two [3%] 
with vomiting (two [6%] vs none). 
Of the 15 patients who developed grade 3 or worse diarrhoea, one event was of grade 4 severity, 
occurring in a patient on the 14-day schedule. Grade 3 or worse diarrhoea occurred with a 
median onset of 88 days (range 1-121) in the 14-day group and 90 days (8-107) in the 21-day 
group. The median duration of grade 3 or worse diarrhoea was 8.5 days (1-16) in patients on the 
14-day schedule and 16 days (2-39) in those on the 21-day schedule. Review of the 51 patients 
who developed diarrhoea of any grade revealed that the protocol- stipulated antidiarrhoeal 
supportive care and retreatment guidelines were not followed for 30 patients (59%). This 
number included ten patients who did not receive any antidiarrhoeal supportive care, 15 
patients who were administered etirinotecan pegol in a setting of unresolved diarrhoea, and 
failure to dose reduce for grade 3 or worse diarrhoea in one patient. Additional patients were 
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not compliant with loperamide administration guidelines (not initiating treatment with grade 1-
2 diarrhoea, as required by the protocol). One patient might have had toxicity that was 
consistent with an anticholinergic syndrome consisting of mild diarrhoea, watery eyes, blurred 
vision, and salivary hypersecretion that occurred once on study day 85; this patient was given 
atropine and the symptoms resolved in 1 day without recurrence on re-treatment. 
Myelosuppression was infrequent. Grade 3 or worse neutropenia occurred in four patients, 
anaemia in one patient, and thrombocytopenia in one patient on the 14-day schedule and in four 
patients, one patient, and no patients, respectively, on the 21-day schedule. Neutropenia of any 
grade occurred in 13 (19%) of 70 patients (six [17%] patients on the 14-day schedule vs seven 
[20%] patients on the 21-day schedule), with febrile neutropenia occurring in one patient. 
Alopecia was rare (ten patients with grade 1; one patient with grade 2). No cardiotoxicity of any 
grade was reported. 
The proportion of patients who discontinued study drug because of drug-related adverse events 
was similar between groups (eight [23%] patients on the 14-day schedule and six [17%] 
patients on the 21-day schedule). Diarrhoea led to discontinuation in three (9%) patients on the 
14-day schedule and two (6%) on the 21-day schedule. 
Overall, four people died within the 30-day period after the last dose of study drug. Of these, two 
were considered possibly related to etirinotecan pegol and occurred in patients on the 14-day 
schedule (one patient with acute renal failure and one with septic shock). The other two deaths 
that occurred within 30 days of last dose were thought to be related to disease progression (one 
patient on each schedule). Six additional patients were listed as having a fatal adverse event 
more than 30 days after last dose of study drug, none of which was thought to be related to 
study drug. These adverse events included disease progression (four patients), pneumonia (one 
patient), and pneumonitis (one patient). 
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Table3. Subgroup analysis of efficacy variables 
 Etirinotecan pegol 145 mg/m2 
every 14 day (n=35) 
Etirinotecan pegol 145 mg/m2 
every 21 days (n=35) 
Triple-negative breast cancer n=11 n=10 
Objective response* 2 (18%, 2.3-51.8) 5 (50%, 18.7-81.3) 
Clinical benefit† 3 (27%, 6.0-61.0) 5 (50%, 18.7-81.3) 
Progression-free survival 
Progressed and/or died 11 (100%) 10 (100%) 
Duration, months 2.9 (0.9-5.7) 4.8 (1.2-5.6) 
Overall survival 
Died 11 (100%) 8 (80%) 
Duration, months 5.7 (2.1-15.1) 9.1 (2.2-10.4) 
Anthracycline and taxane n=23 n=21 
Objective response* 7 (30%, 13.2-52.9) 5 (24%, 8.2-47.2) 
Clinical benefit† 9 (39%, 19.7-61.5) 8 (38%, 18.1-61.6) 
Progression-free survival 
Progressed and/or died 21 (91%) 17(81%) 
Duration, months 3.2 (1.5-6.9) 5.1 (1.4-7.2) 
Overall survival 
Died 17 (74%) 13 (62%) 
Duration, months 12.0 (5.4-15.8) 13.9 (8.6-NE) 
Anthracycline, taxane, and capecitabine n=8 n=10 
Objective response* 2 (25%, 3.2-65.1) 4 (40%, 12.2-73.8) 
Clinical benefit† 2 (25%, 3.2-65.1) 7 (70%, 34.8-93.3) 
Progression-free survival 
Progressed and/or died 7 (88%) 9 (90%) 
Duration, months 3.8 (1.3-10.9) 6.2 (1.1-9.1) 
Overall survival 
Died 6 (75%) 6 (60%) 
Duration, months 8.2 (2.1-NE) 12.7 (3.6-NE) 
Data are number (%, 95% CI), number (%), or median (95% CI). NE=not estimable. *Complete response or partial 
response. †Complete reponse, partial response, or stable disease for ≥6 months. 
We used data from the 43 patients who had pretreatment and post-treatment measurements of 
CA27-29 in our exploratory analyses to assess the correlation between a change in CA27-29 
concentration and tumour size (figure 3). Of the 15 patients within this subset with a complete 
or partial response, 14 (93%) had at least a 10% decline in CA27-29; five (83%) of six patients 
who had stable disease for 6 months or longer also had a 10% or greater reduction in CA27-29. 
Of the 11 patients with progressive disease, nine (82%) patients had increases in CA27-29 from 
baseline. 
Further exploratory analyses included assessment of UGT1A1 and ABCC2 polymorphisms and 
their association with the incidence of selected toxicities. UGT1A1 status was available for 66 
patients; however, only five patients were poor metabolisers (ie, they had TA 7/7, 7/8, or 8/8 
genotypes). No association between UGT1A1 status and either neutropenia or diarrhoea could 
be made. ABCC2 status was also available for 66 patients. Only two patients were homozygous 
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for the ABCC2 24C→T mutation, and three patients were homozygous for the ABCC2 3972G→A 
mutation; no obvious pattern for neutropenia or diarrhoea was seen. A separate population-
based analysis of combined phase 1 and 2 data for these polymorphisms is underway. 
Table 4. Adverse events 
 Etirinotecan pegol 145 mg/m2 every 
14 days (n=35) 
Etirinotecan pegol 145 mg/m2 
every 21 days (n=35) 
All patients (n=70) 
All grades Grade 3 Grade 4 Grade 
5 
All grades Grade 3 Grade 
4 
Grade 5 All grades Grade 3 Grade 
4 
Grade 5 
Treatment-emergent AEs occurring in >10% of patients and all grade 5 AEs 
Diarrhoea 24 (69%) 6 (17%) 1 (3%) 0 27 (77%) 8 (23%) 0 0 51 (73%) 14 
(20%) 
1 (1%) 0 
Nausea 25 (71%) 2 (6%) 0 0 26 (74%) 1 (3%) 0 0 51 (73%) 3 (4%) 0 0 
Fatigue 15 (43%) 5 (14%) 0 0 18 (51%) 3 (9%) 0 0 33(47%) 8 (11%) 0 0 
Vomiting 19 (54%) 3 (9%) 0 0 14 (40%) 2 (6%) 0 0 33(47%) 5 (7%) 0 0 
Decreased appetite 14 (40%) 1 (3%) 0 0 12 (34%) 0 0 0 26 (37%) 1 (1%) 0 0 
Constipation 14 (40%) 0 0 0 9 (26%) 0 0 0 23 (33%) 0 0 0 
Abdominal pain 7 (20%) 1 (3%) 0 0 8 (23%) 0 0 0 15 (21%) 1 (1%) 0 0 
Blurred vision 9 (26%) 0 0 0 6 (17%) 0 0 0 15 (21%) 0 0 0 
Dehydration 7 (20%) 3 (9%) 0 0 6 (17%) 4 (11%) 0 0 13 (19%) 7 (10%) 0 0 
Neutropenia 6 (17%) 2 (6%) 2 (6%) 0 7 (20%) 3 (9%) 1 (3%) 0 13 (19%) 5 (7%) 3 (4%) 0 
Alopecia 7 (20%) 0 0 0 4 (11%) 0 0 0 11 (16%) 0 0 0 
Anaemia 6 (17%) 1 (3%) 0 0 4 (11%) 0 1 (3%) 0 10 (14%) 1 (1%) 1 (1%) 0 
Decreased weight 3 (9%) 0 0 0 7 (20%) 0 0 0 10 (14%) 0 0 0 
Dyspnea 6 (17%) 1 (3%) 0 0 3 (9%) 0 0 0 9 (13%) 1 (1%) 0 0 
Headache 4 (11%) 0 0 0 4 (11%) 0 0 0 8 (11%) 0 0 0 
Lethargy 3 (9%) 1 (3%) 0 0 5 (14%) 0 0 0 8 (11%) 1 (1%) 0 0 
Pyrexia 5 (14%) 0 0 0 3 (9%) 0 0 0 8 (11%) 0 0 0 
Upper-abdominal pain 3 (9%) 0 0 0 4 (11%) 0 0 0 7 (10%) 0 0 0 
Dizziness 4 (11%) 1 (3%) 0 0 3 (9%) 1 (3%) 0 0 7 (10%) 2 (3%) 0 0 
Dry mouth 3 (9%) 0 0 0 4 (11%) 0 0 0 7 (10%) 0 0 0 
Dysgeusia 3 (9%) 0 0 0 4 (11%) 0 0 0 7 (10%) 0 0 0 
Acute renal failure* 1 (3%) 0 0 1 (3%) 0 0 0 0 1 (1%) 0 0 1 (1%) 
Septic shock* 1 (3%) 0 0 1 (3%) 0 0 0 0 1 (1%) 0 0 1 (1%) 
Any treatment-emergent AEs occurring in all patients 
Any treatment-
emergent AE 
35 (100%) 13 
(37%) 








6 (9%) 4 (6%) 
≥1 serious AE 18 (51%) •• •• •• 15 (43%) •• •• •• 33(47%) •• •• •• 
Data are number of patients who had an event (% of patients). AE=adverse event. *These toxicities were thought to 
be possibly drug-related fatalities and are listed despite not meeting the threshold of at least 10% incidence 
Discussion 
In this randomised phase 2 trial, single-agent etirinotecan pegol showed clinical activity in 
pretreated patients with aggressive advanced breast cancer, thus validating previous phase 2 
data that showed anticancer activity for topoisomerase inhibition in advanced disease.13 
For patients with incurable, advanced breast cancer, chemotherapy is directed at extending life 
while maintaining a reasonable quality of life. As such, standard of care is typically sequential 
single-agent therapy at maximally tolerated doses. Etirinotecan pegol exceeded the efficacy 
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threshold of five or more responses per group, with ten of 35 patients in each treatment 
schedule responding to treatment, including patients with visceral disease. Toxicity was mainly 
gastrointestinal; myelosuppression was rare, cardiotoxicity and neurotoxicity were absent, and 
alopecia was minimal. Placing these results in context (panel), studies assessing single-agent 
intravenous compounds ixabepilone,2,17 eribulin,3,16,18 and albuminbound paclitaxel19 
(comparing two doses) reported objective responses of 12%, 9-12%, and 14-16%, respectively, 
for patients with advanced breast cancer who had received a previous anthracycline or taxane 
(toxicities typically included severe myelosuppression, neuropathy, and alopecia). The oral 
compounds sunitinib,20,21 capecitabine,21 sorafenib,22 and everolimus23 produced objective 
responses of 11%, 16%, 0%, and 12%, respectively; common toxicities included fatigue, 
gastrointestinal toxicity (nausea, diarrhoea, and anorexia), skin rash, and mucositis. Median PFS 
for the intravenous compounds was 2.2-3.1 months (ixabepilone), 2.6-3.7 months (eribulin), 
and 3.0-3.5 months (albumin-bound paclitaxel); for the oral compounds, PFS was 2.8 months 
(sunitinib), 4.2 months (capecitabine), and 2.0 months (sorafenib), and was not reported for 
everolimus. 
Although the proportion of patients who achieved an objective response was identical between 
the two schedules, etirinotecan pegol on the 21-day schedule had a generally more favourable 
toxicity profile despite the extended time on study. Patients on the 21-day schedule had less 
drug-related grade 3 or worse toxicity and fewer discontinued because of drug-related toxicity 
than did those on the 14-day schedule, and no grade 4 diarrhoea or drug-related deaths was 
reported in this group. A comparison of baseline demographics between the two groups did not 
show any substantial difference to account for this difference in tolerability. Some 
characteristics might favour the 21-day schedule group (slightly younger age, longer median 
time from primary diagnosis to study entry, and longer median time from diagnosis of 
metastatic disease to study entry); however, other characteristics might favour the 14-day 
schedule group (fewer patients with an ECOG performance status of 1, fewer patients with 
visceral disease, and a lower average number of previous cytotoxic regimens for advanced 
disease). 
Phase 2 trials investigating several doses, schedules, or infusion lengths are common in breast 
cancer, providing crucial information about the best possible administration of a cytotoxic drug 
for future phase 3 investigations. Recent examples include trials of ixabepilone,17 eribulin,16 
albumin-bound paclitaxel,19 and everolimus.23 The results of our randomised phase 2 study led 
to selection of the 21-day schedule for a subsequent phase 3 trial comparing etirinotecan pegol 
in patients with advanced breast cancer with a treatment of physician’s choice (NCT01492101). 
Etirinotecan pegol showed efficacy in subsets of patients with triple-negative breast cancer and 
those who had previously received anthracycline, taxane, and capecitabine. Although numbers of 
patients in each of these subgroups was small, efficacy was generally more favourable with the 
21-day schedule and compared favourably with responses seen with other single agents.2,3,24-28 
Although our results seem promising they are based on small subsets of patients and intertrial 
comparisons should always be viewed with caution. 
Delayed diarrhoea was the most common serious toxicity associated with etirinotecan pegol. 
Compliance with protocol-stipulated antidiarrhoeal supportive care, re-treatment guidelines, 
and dose reduction for grade 3 or worse diarrhoea was regarded as unacceptable in 30 (59%) of 
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the 51 patients who reported at least one episode of diarrhoea. Increased monitoring of 
antidiarrhoeal supportive care and re-treatment practices in continuing etirinotecan pegol trials 
is in place to assure that patients receive appropriate care at first occurrence, lowering the risk 
of escalation to more severe toxicity. Treatment delays to allow resolution of diarrhoea can be 
implemented without interruption of continuous exposure to SN38. 
Figure 3. Change in serum CA27-29 over time, by response 
 
Percentage change in CA27-29 over time in patients with a complete or partial response (A), stable disease for 6 
months or longer (B), stable disease for less than 6 months (C), and progressive disease (D) as defined by Response 
Evaluation Criteria in Solid Tumors (version 1.0). Solid lines represent individual patients. Datapoints above the 
dotted horizontal line show an increase in CA27-19 from baseline; datapoints below the dotted horizontal line show a 
decrease in CA27-19 from baseline. The first CA27-29 measurement was obtained during the 28-day screening period, 
not immediately before dosing at week 0. CA27-29=cancer antigen 27-29. 
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Panel: Research in context 
Systematic review 
We searched PubMed and the American Society of Clinical Oncology database for reports 
published in English between Jan 1, 2007, and Aug 1, 2013, with the terms “breast cancer”, 
“phase 2”, or “phase II”, and “taxane and anthracycline resistant”. Clinical trials for the following 
single-agent chemotherapeutics were discovered: ixabepilone,24547 eribulin,348 albumin-bound 
paclitaxel,19 sunitinib,20-21 sorafenib,22 capecitabine,21 and everolimus.23 The anticancer 
mechanism of action varies for these drugs: ixabepilone, eribulin, and albumin-bound paclitaxel 
(all intravenous) target tubulin; sunitinib and sorafenib (oral) each target multiple receptor 
tyrosine kinases; capecitabine is regarded as an antimetabolite; and everolimus targets mTOR. 
We searched the published clinical trials for signs of anticancer activity, including the 
proportions of patients who achieved an objective response and progression-free survival. 
Overall survival was not uniformly reported. 
Interpretation 
The results of our randomised phase 2 study, when combined with those of previous phase 2 
trials and other related studies, led to the selection of the 21-day schedule for a subsequent 
phase 3 trial comparing etirinotecan pegol to treatment of physician’s choice in patients with 
breast cancer whose disease had progressed after receiving anthracycline, taxane, and 
capecitabine. 
 
As shown in the phase 1 clinical trial,5 the plasma concentrations of both irinotecan and SN38 
after etirinotecan pegol administration showed that there was sustained and controlled systemic 
exposure, which probably contributed to the absence of cholinergic toxicities and low rate of 
neutropenia, while maintaining evidence of antitumour response. Maximal irinotecan plasma 
concentrations—the moiety responsible for cholinergic toxicities temporarily associated with an 
irinotecan infusion (eg, rhinitis, increased salivation, miosis, lacrimation, diaphoresis, flushing, 
and intestinal hyperperistalsis)—are about 35 times lower with etirinotecan pegol than with 
typical irinotecan administration.29 These lower plasma concentrations are probably 
contributing to the absence of cholinergic toxicities with etirinotecan pegol, precluding the 
necessity of atropine premedication before etirinotecan pegol infusions. Similarly, maximal 
SN38 concentrations are at least 6-10 times lower with etirinotecan pegol than with standard 
irinotecan administration, possibly decreasing the incidence of severe neutropenia, which was 
infrequent after administration of etirinotecan pegol, occurring in just four patients in each 
group without any neutropenia-related deaths. Several other toxicities associated with common 
chemotherapies used in breast cancer were absent or occurred at a low frequency in this trial, 
including neuropathy, alopecia, and cardiotoxicity. This tolerability profile suggests that 
etirinotecan pegol offers a treatment option with a different toxicity profile compared with other 
frequently used chemotherapy agents for breast cancer. 
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